Supratentorial Low-Grade Glioma and Glioneuronal Tumors

Status: draft · Last updated 2026-11-13 · By Jason S. Hauptman, MD, PhD (AI-assisted)

Read in the interactive book →

High-yield points

  • Overall: pLGG is a MAPK pathway disease; a driver is found in 84% .
    • Fusions: behave indolently.
    • BRAF V600E: worse, especially with CDKN2A deletion .
  • Key molecular markers:
    • Ganglioglioma: BRAF V600E in about 20–40% .
    • PXA: BRAF V600E in about 65% .
    • DNET: FGFR1, and never V600E .
    • PLNTY: FGFR2/3 or V600E, CD34-positive, calcified, temporal .
    • Angiocentric glioma: MYB–QKI .
  • Tumor control: GTR is the main predictor of PFS. After surgery alone, OS is about 96–97% .
  • Seizure control:
    • Overall: about 80% Engel I.
    • Predictors: GTR (OR 5.3) and epilepsy of 1 year or less (OR 9.5) .
    • Practice: operate early and remove the whole lesion plus adjacent dysplasia.
  • LITT: an option for deep or eloquent and recurrent LGG :
    • Effect: tumor volume falls in about 80%, and 90% need no further surgery.
    • Risk: permanent deficits in about 5–6%. Complications rise 14% per cm³ of ablation.
    • Biopsy first, and keep the ablation volume small.
  • Targeted therapy:
    • BRAF V600: dabrafenib + trametinib beat carboplatin/vincristine first line (47% vs. 11% response) .
    • MEK inhibitors: active in BRAF-altered and NF1 tumors .
  • Avoid radiation in hemispheric LGG. It adds no survival benefit, and all three malignant transformations in one series followed it .

Landmark papers

  • COG natural-history study (Wisoff et al., Neurosurgery 2011): 518 evaluable low-grade gliomas managed by surgery alone. 5- and 8-year OS were 97% and 96% and PFS 80% and 78%, and GTR without residual was the dominant predictor of PFS .
  • Dabrafenib plus trametinib (Bouffet et al., N Engl J Med 2023): a randomized phase 2 trial (110 patients) of first-line therapy. Response was 47% vs 11% with carboplatin/vincristine, and median PFS 20.1 vs 7.4 months .

Pediatric low-grade gliomas (pLGG) are the most common CNS tumors of childhood .

Jason S. Hauptman, MD, PhD© 2026 Jason S. Hauptman, MD, PhD. All rights reserved. Original figure from Hauptman's High Yield Thoughts in Pediatric Neurosurgery (pedsneurosurg.org). Do not copy, reproduce, redistribute or adapt without written permission.https://www.pedsneurosurg.org/hy-peds-ns:lgg_glioneuronal:729c0d078fcea13e© 2026 Jason S. Hauptman, MD, PhD. All rights reserved. Original figure; please do not copy, reproduce or redistribute without written permission.Lateral view of a child's left hemisphere with the typical sites and appearance of ganglioglioma, DNET, PLNTY, PXA and angiocentric gliomaEPILEPSY-ASSOCIATED LOW-GRADE TUMORS (LATERAL LEFT HEMISPHERE, ANTERIOR LEFT)Angiocentric glioma: cortical;MYB–QKIPXA: superficial, meningealcontact; BRAF V600E ~65%DNET: intracortical,multinodular; FGFR1Ganglioglioma: temporal; cyst +nodule; BRAF V600E in ~20–40%PLNTY: temporal, calcified,infiltrative; BRAF V600E or FGFR2/3Typical sites and appearance; schematic, not to scale
Typical sites and appearance of supratentorial low-grade glioneuronal and glial tumors in children, lateral view of the left hemisphere. Ganglioglioma: temporal, with a cyst and mural nodule. DNET: an intracortical, multinodular "bubbly" lesion without mass effect. PLNTY: temporal, calcified and infiltrative. Pleomorphic xanthoastrocytoma: superficial, cystic, with a nodule abutting the meninges. Angiocentric glioma: a subtle cortical lesion. Not to scale.

WHO 2021 framework

1. Pediatric-type diffuse low-grade gliomas: - diffuse astrocytoma, MYB- or MYBL1-altered; - angiocentric glioma; - PLNTY; - diffuse LGG, MAPK-altered. 2. Circumscribed astrocytic gliomas: - pilocytic astrocytoma (see its own topic); - pleomorphic xanthoastrocytoma (PXA); - SEGA. 3. Glioneuronal and neuronal tumors: - ganglioglioma; - DNET; - DIG/DIA; - myxoid glioneuronal tumor; - MVNT; - DGONC; - others.

The main entities

Surgery: tumor control

Surgery: seizure control

Laser interstitial thermal therapy (LITT)

Medical and targeted therapy

Related topics

References

  1. Wisoff JH, Sanford RA, Heier LA, et al. Primary neurosurgery for pediatric low-grade gliomas: a prospective multi-institutional study from the Children's Oncology Group. Neurosurgery 2011;68(6):1548–1554. doi:10.1227/NEU.0b013e318214a66e. PMID 21368693. verified
  2. Ryall S, Zapotocky M, Fukuoka K, et al. Integrated molecular and clinical analysis of 1,000 pediatric low-grade gliomas. Cancer Cell 2020;37(4):569–583.e5. doi:10.1016/j.ccell.2020.03.011. PMID 32289278. verified
  3. Blumcke I, Spreafico R, Haaker G, et al. Histopathological findings in brain tissue obtained during epilepsy surgery. N Engl J Med 2017;377(17):1648–1656. doi:10.1056/NEJMoa1703784. PMID 29069555. verified
  4. Bale TA, Rosenblum MK. The 2021 WHO Classification of Tumors of the Central Nervous System: an update on pediatric low-grade gliomas and glioneuronal tumors. Brain Pathol 2022;32(4):e13060. doi:10.1111/bpa.13060. PMID 35218102. verified
  5. Bonney PA, Glenn CA, Ebeling PA, et al. Seizure freedom rates and prognostic indicators after resection of gangliogliomas: a review. World Neurosurg 2015;84(6):1988–1996. doi:10.1016/j.wneu.2015.06.044. PMID 26123501. verified
  6. Schindler G, Capper D, Meyer J, et al. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol 2011;121(3):397–405. doi:10.1007/s00401-011-0802-6. PMID 21274720. verified
  7. Dahiya S, Haydon DH, Alvarado D, et al. BRAF(V600E) mutation is a negative prognosticator in pediatric ganglioglioma. Acta Neuropathol 2013;125(6):901–910. doi:10.1007/s00401-013-1120-y. PMID 23609006. verified
  8. Rivera B, Gayden T, Carrot-Zhang J, et al. Germline and somatic FGFR1 abnormalities in dysembryoplastic neuroepithelial tumors. Acta Neuropathol 2016;131(6):847–863. doi:10.1007/s00401-016-1549-x. PMID 26920151. verified
  9. Chang EF, Christie C, Sullivan JE, et al. Seizure control outcomes after resection of dysembryoplastic neuroepithelial tumor in 50 patients. J Neurosurg Pediatr 2010;5(1):123–130. doi:10.3171/2009.8.PEDS09368. PMID 20043747. verified
  10. Huse JT, Snuderl M, Jones DT, et al. Polymorphous low-grade neuroepithelial tumor of the young (PLNTY): an epileptogenic neoplasm with oligodendroglioma-like components, aberrant CD34 expression, and genetic alterations involving the MAP kinase pathway. Acta Neuropathol 2017;133(3):417–429. doi:10.1007/s00401-016-1639-9. PMID 27812792. verified
  11. Ida CM, Johnson DR, Nair AA, et al. Polymorphous low-grade neuroepithelial tumor of the young (PLNTY): molecular profiling confirms frequent MAPK pathway activation. J Neuropathol Exp Neurol 2021;80(9):821–829. doi:10.1093/jnen/nlab075. PMID 34363682. verified
  12. Ida CM, Rodriguez FJ, Burger PC, et al. Pleomorphic xanthoastrocytoma: natural history and long-term follow-up. Brain Pathol 2015;25(5):575–586. doi:10.1111/bpa.12217. PMID 25318587. verified
  13. Bandopadhayay P, Ramkissoon LA, Jain P, et al. MYB-QKI rearrangements in angiocentric glioma drive tumorigenicity through a tripartite mechanism. Nat Genet 2016;48(3):273–282. doi:10.1038/ng.3500. PMID 26829751. verified
  14. Pollack IF, Claassen D, al-Shboul Q, et al. Low-grade gliomas of the cerebral hemispheres in children: an analysis of 71 cases. J Neurosurg 1995;82(4):536–547. doi:10.3171/jns.1995.82.4.0536. PMID 7897512. verified
  15. Englot DJ, Berger MS, Barbaro NM, Chang EF. Factors associated with seizure freedom in the surgical resection of glioneuronal tumors. Epilepsia 2012;53(1):51–57. doi:10.1111/j.1528-1167.2011.03269.x. PMID 21933181. verified
  16. Bonney PA, Boettcher LB, Conner AK, et al. Review of seizure outcomes after surgical resection of dysembryoplastic neuroepithelial tumors. J Neurooncol 2016;126(1):1–10. doi:10.1007/s11060-015-1961-4. PMID 26514362. verified
  17. Lassaletta A, Zapotocky M, Mistry M, et al. Therapeutic and prognostic implications of BRAF V600E in pediatric low-grade gliomas. J Clin Oncol 2017;35(25):2934–2941. doi:10.1200/JCO.2016.71.8726. PMID 28727518. verified
  18. Bouffet E, Hansford JR, Garrè ML, et al. Dabrafenib plus trametinib in pediatric glioma with BRAF V600 mutations. N Engl J Med 2023;389(12):1108–1120. doi:10.1056/NEJMoa2303815. PMID 37733309. verified
  19. Fangusaro J, Onar-Thomas A, Young Poussaint T, et al. Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial. Lancet Oncol 2019;20(7):1011–1022. doi:10.1016/S1470-2045(19)30277-330277-3). PMID 31151904. verified
  1. Arocho-Quinones EV, Lew SM, Handler MH, et al. Magnetic resonance-guided stereotactic laser ablation therapy for the treatment of pediatric brain tumors: a multiinstitutional retrospective study. J Neurosurg Pediatr 2020;26(1):13–21. doi:10.3171/2020.1.PEDS19496. PMID 32217793. verified
  2. O'Leary S, Haider MA, Truong N, et al. Stereotactic laser ablation for pediatric central nervous system tumors: a systematic review and meta-analysis of the literature. J Neurosurg Pediatr 2025;36(2):230–243. doi:10.3171/2025.1.PEDS24387. PMID 40344762. verified
  3. Tovar-Spinoza Z, Choi H. MRI-guided laser interstitial thermal therapy for the treatment of low-grade gliomas in children: a case-series review, description of the current technologies and perspectives. Childs Nerv Syst 2016;32(10):1947–1956. doi:10.1007/s00381-016-3193-0. PMID 27659837. verified

Verification (2026-11-13): each reference's authors, title, journal, volume, pages, DOI and PMID were checked on PubMed. Numbers were checked against the PubMed abstracts.

Caveats: